There is an ongoing debate as to whether SARS-CoV-2 antibodies can be found in patients who have recovered from COVID-19 disease. Currently, there is no consensus on whether the antibodies, if present, are protective. Our regular measurements of SARS-CoV-2 antibodies, starting in July 2020, have provided us with the opportunity of becoming acquainted with the five different immunoassays. A total of 149 patients were enrolled in our study. We measured the samples using each immunoassay, then performing a virus neutralization test and comparing the results of SARS-CoV-2 antibodies with this test. We observed that the production of neutralizing antibodies is age-dependent. Elderly patients have a higher proportion of high neutralizing titers than young patients. Based on our results, and in combination with the literature findings, we can conclude that the serological SARS-CoV-2 antibody measurement is a helpful tool in the fight against COVID-19. The assays can provide information about the patient's previous contact with the virus. Anti-spike protein assays correlate well with the virus neutralization test and can be used in the screening of potential convalescent plasma donors.

Department of Biomedical Sciences Faculty of Medicine University of Ostrava 703 00 Ostrava Czech Republic

Department of Immunochemistry Diagnostics University Hospital in Pilsen 309 55 Pilsen Czech Republic

Department of Infectious Diseases and Travel Medicine University Hospital in Pilsen 309 55 Pilsen Czech Republic

Department of Microbiology University Hospital in Pilsen 309 55 Pilsen Czech Republic

Department of Otorhinolaryngology University Hospital in Pilsen Faculty of Medicine in Pilsen Charles University 305 99 Pilsen Czech Republic

Department of Virology Public Health Institute 702 00 Ostrava Czech Republic

Faculty of Science Palacky University in Olomouc 779 00 Olomouc Czech Republic

Institute of Epidemiology Faculty of Medicine in Pilsen Charles University 305 99 Pilsen Czech Republic

Institute of Pharmacology and Toxicology Faculty of Medicine in Pilsen Charles University 323 00 Pilsen Czech Republic

Laboratory of Immunology Gennet 110 00 Prague Czech Republic

Zobrazit více v PubMed

Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical Features of Patients Infected with 2019 Novel Coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5. PubMed DOI PMC

COVID-19 Dashboard by the Center for Systems Science and Engineering (CSSE) at Johns Hopkins University (JHU) [(accessed on 2 March 2021)]; Available online: https://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6.

Poland G.A., Ovsyannikova I.G., Kennedy R.B. SARS-CoV-2 Immunity: Review and Applications to Phase 3 Vaccine Candidates. Lancet. 2020;396:1595–1606. doi: 10.1016/S0140-6736(20)32137-1. PubMed DOI PMC

Sekine T., Perez-Potti A., Rivera-Ballesteros O., Strålin K., Gorin J.-B., Olsson A., Llewellyn-Lacey S., Kamal H., Bogdanovic G., Muschiol S., et al. Robust T Cell Immunity in Convalescent Individuals with Asymptomatic or Mild COVID-19. Cell. 2020;183:158–168.e14. doi: 10.1016/j.cell.2020.08.017. PubMed DOI PMC

Kellam P., Barclay W. The Dynamics of Humoral Immune Responses Following SARS-CoV-2 Infection and the Potential for Reinfection. J. Gen. Virol. 2020;101:791–797. doi: 10.1099/jgv.0.001439. PubMed DOI PMC

Callow K.A., Parry H.F., Sergeant M., Tyrrell D.A. The Time Course of the Immune Response to Experimental Coronavirus Infection of Man. Epidemiol. Infect. 1990;105:435–446. doi: 10.1017/S0950268800048019. PubMed DOI PMC

Ledford H. Coronavirus Reinfections: Three Questions Scientists Are Asking. Nature. 2020;585:168–169. doi: 10.1038/d41586-020-02506-y. PubMed DOI

Pickering S., Betancor G., Galão R.P., Merrick B., Signell A.W., Wilson H.D., Kia Ik M.T., Seow J., Graham C., Acors S., et al. Comparative Assessment of Multiple COVID-19 Serological Technologies Supports Continued Evaluation of Point-of-Care Lateral Flow Assays in Hospital and Community Healthcare Settings. PLoS Pathog. 2020;16:e1008817. doi: 10.1371/journal.ppat.1008817. PubMed DOI PMC

Wrapp D., Wang N., Corbett K.S., Goldsmith J.A., Hsieh C.-L., Abiona O., Graham B.S., McLellan J.S. Cryo-EM Structure of the 2019-NCoV Spike in the Prefusion Conformation. Science. 2020;367:1260–1263. doi: 10.1126/science.abb2507. PubMed DOI PMC

Litzba N., Zelená H., Kreil T.R., Niklasson B., Kühlmann-Rabens I., Remoli M.E., Niedrig M. Evaluation of Different Serological Diagnostic Methods for Tick-Borne Encephalitis Virus: Enzyme-Linked Immunosorbent, Immunofluorescence, and Neutralization Assay. Vector Borne Zoonotic Dis. 2014;14:149–159. doi: 10.1089/vbz.2012.1287. PubMed DOI

Casadevall A., Pirofski L. The Convalescent Sera Option for Containing COVID-19. J. Clin. Investig. 2020;130:1545–1548. doi: 10.1172/JCI138003. PubMed DOI PMC

Duan K., Liu B., Li C., Zhang H., Yu T., Qu J., Zhou M., Chen L., Meng S., Hu Y., et al. Effectiveness of Convalescent Plasma Therapy in Severe COVID-19 Patients. Proc. Natl. Acad. Sci. USA. 2020;117:9490–9496. doi: 10.1073/pnas.2004168117. PubMed DOI PMC

Fejt V., Krátká Z., Zelená H., Fürst T. Age Is Not a Disease: Evolution of Protective Antibodies against SARS-CoV-2 in Seniors from the Brevnice Nursing Home. Cas Lek Cesk. 2020;159:303–311. PubMed

Valcourt E.J., Manguiat K., Robinson A., Chen J.C.-Y., Dimitrova K., Philipson C., Lamoureux L., McLachlan E., Schiffman Z., Drebot M.A., et al. Evaluation of a Commercially-Available Surrogate Virus Neutralization Test for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2) Diagn. Microbiol. Infect. Dis. 2021;99:115294. doi: 10.1016/j.diagmicrobio.2020.115294. PubMed DOI PMC

Yongchen Z., Shen H., Wang X., Shi X., Li Y., Yan J., Chen Y., Gu B. Different Longitudinal Patterns of Nucleic Acid and Serology Testing Results Based on Disease Severity of COVID-19 Patients. Emerg. Microbes Infect. 2020;9:833–836. doi: 10.1080/22221751.2020.1756699. PubMed DOI PMC

Letko M., Marzi A., Munster V. Functional Assessment of Cell Entry and Receptor Usage for SARS-CoV-2 and Other Lineage B Betacoronaviruses. Nat. Microbiol. 2020;5:562–569. doi: 10.1038/s41564-020-0688-y. PubMed DOI PMC

Afzal N., Tariq N., Raza S., Shakeel D. Diagnostic Accuracy of Electro-Chemiluminescence Immunoassay Anti-SARS-CoV-2 Serological Test. Cureus. 2021;13:e12588. PubMed PMC

Irsara C., Egger A.E., Prokop W., Nairz M., Loacker L., Sahanic S., Pizzini A., Sonnweber T., Mayer W., Schennach H., et al. Evaluation of Four Commercial, Fully Automated SARS-CoV-2 Antibody Tests Suggests a Revision of the Siemens SARS-CoV-2 IgG Assay. Clin. Chem. Lab. Med. 2021 doi: 10.1515/cclm-2020-1758. published Ahead of print. PubMed DOI

Weidner L., Gänsdorfer S., Unterweger S., Weseslindtner L., Drexler C., Farcet M., Witt V., Schistal E., Schlenke P., Kreil T.R., et al. Quantification of SARS-CoV-2 Antibodies with Eight Commercially Available Immunoassays. J. Clin. Virol. 2020;129:104540. doi: 10.1016/j.jcv.2020.104540. PubMed DOI PMC

Ghaffari A., Meurant R., Ardakani A. COVID-19 Serological Tests: How Well Do They Actually Perform? Diagnostics. 2020;10:453. doi: 10.3390/diagnostics10070453. PubMed DOI PMC

Amanat F., Krammer F. SARS-CoV-2 Vaccines: Status Report. Immunity. 2020;52:583–589. doi: 10.1016/j.immuni.2020.03.007. PubMed DOI PMC

Freedenberg A.T., Pan C., Diehl W.E., Romeiser J.L., Hwang G., Leiton C.V., Muecksch F., Shroyer K.R., Bennett-Guerrero E. Neutralizing Activity to SARS-CoV-2 of Convalescent and Control Plasma Used in a Randomized Controlled Trial. Transfusion. 2021:1–7. doi: 10.1111/trf.16283. PubMed DOI PMC

Salazar E., Kuchipudi S.V., Christensen P.A., Eagar T.N., Yi X., Zhao P., Jin Z., Long S.W., Olsen R.J., Chen J., et al. Relationship between Anti-Spike Protein Antibody Titers and SARS-CoV-2 In Vitro Virus Neutralization in Convalescent Plasma. bioRxiv. 2020 doi: 10.1101/2020.06.08.138990. DOI

Suhandynata R.T., Hoffman M.A., Huang D., Tran J.T., Kelner M.J., Reed S.L., McLawhon R.W., Voss J.E., Nemazee D., Fitzgerald R.L. Commercial Serology Assays Predict Neutralization Activity against SARS-CoV-2. Clin. Chem. 2021;67:404–414. doi: 10.1093/clinchem/hvaa262. PubMed DOI PMC

Gniadek T.J., Thiede J.M., Matchett W.E., Gress A.R., Pape K.A., Fiege J.K., Jenkins M.K., Menachery V.D., Langlois R.A., Bold T.D. SARS-CoV-2 Neutralization and Serology Testing of COVID-19 Convalescent Plasma from Donors with Nonsevere Disease. bioRxiv. 2020 doi: 10.1111/trf.16101. PubMed DOI PMC

Valdivia A., Torres I., Latorre V., Francés-Gómez C., Albert E., Gozalbo-Rovira R., Alcaraz M.J., Buesa J., Rodríguez-Díaz J., Geller R., et al. Inference of SARS-CoV-2 Spike-Binding Neutralizing Antibody Titers in Sera from Hospitalized COVID-19 Patients by Using Commercial Enzyme and Chemiluminescent Immunoassays. Eur. J. Clin. Microbiol. Infect. Dis. 2021;40:485–494. doi: 10.1007/s10096-020-04128-8. PubMed DOI PMC

Post N., Eddy D., Huntley C., van Schalkwyk M.C.I., Shrotri M., Leeman D., Rigby S., Williams S.V., Bermingham W.H., Kellam P., et al. Antibody Response to SARS-CoV-2 Infection in Humans: A Systematic Review. PLoS ONE. 2020;15:e0244126. doi: 10.1371/journal.pone.0244126. PubMed DOI PMC

One Year Duration of Immune Response Following a 3rd Booster Dose of mRNA Vaccine Against COVID-19 in 292 Patients With Hematological Malignancies in University Hospital Ostrava, Czech Republic

Comparative study between virus neutralisation testing and other serological methods detecting anti-SARS-CoV-2 antibodies in Europe, 2021

Wild ungulates as sentinels of flaviviruses and tick-borne zoonotic pathogen circulation: an Italian perspective

Comparison of Two Commercially Available Interferon-γ Release Assays for T-Cell-Mediated Immunity and Evaluation of Humoral Immunity against SARS-CoV-2 in Healthcare Workers

SARS-CoV-2-specific humoral and cellular immune responses to BNT162b2 vaccine in Fibrodysplasia ossificans progressiva patients

Immunogenicity and safety of the booster BNT162b2 vaccine in patients with axial spondyloarthritis treated with biological disease-modifying drugs

Immune Response 5-7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines

Long-Term Monitoring of the Antibody Response to a SARS-CoV-2 Infection